Longeveron Inc. Common Stock

Day range

$1.50 – $1.86

Open

$1.55

Prev close

$1.60

Volume

86.25K

Market cap

$5.1M

Shares out

3.04M

P/E

—

P/S

4.30

P/B

0.49

P/FCF

—

ROE

-225.7%

ROA

-151.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive officer departureOct 14, 2026

  On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026.

• Clinical trial resultsSep 23, 2026

  On September 16, 2026, Longeveron Inc. issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating the Company's investigational stem cell therapy, laromestrocel, as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome ("HLHS"). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction ("RVEF") at Month 12.

• Listing compliance regainedSep 14, 2026

  On September 11, 2026, the Company received written notification from Nasdaq indicating that the Company's Common Stock had a closing price of $1.00 per share or greater for the last 10 consecutive business days, from August 27, 2026 until September 10, 2026, and that, as a result, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

• Stock splitAug 24, 2026

  On July 1, 2026 the stockholders of Longeveron Inc. (the "Company") approved a proposal at the Company's annual meeting of stockholders (the "Annual Meeting") to amend the Company's Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of the Company's Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (collectively, the Company's "Common Stock"), at a ratio between one-for-two (1:2) and one-for-twenty (1:20)... On July 31, 2026, the Company's Board of Directors approved a final reverse stock split ratio of one-for-ten (1:10).

• Executive compensation changeAug 19, 2026

  In connection with his appointment, Mr. Jhaveri has entered into a Letter Agreement (the "Agreement") with the Company, pursuant to which he will be entitled to receive an initial base salary of $400,000 per year, and is eligible to participate in the Company's performance-based annual cash incentive plan, with an award target equal to forty-five percent (45%) of his base salary, as well as short and long-term equity incentive awards pursuant to the terms of the Company's Fourth Amended and Restated 2021 Incentive Award Plan. As of the Effective Date, Mr. Jhaveri will receive an equity award of 300,000 Restricted Stock Units which will vest quarterly over a three-year period.

Days to cover

1.0

Short interest

106.8K

Avg volume

286.64K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Longeveron Announces 1-for-10 Reverse Stock Split
  neutralGlobeNewswire Inc.· Aug 24, 2026
• Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
  positiveBenzinga· Apr 10, 2026
• A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
  positiveBenzinga· Mar 18, 2026
• Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
  positiveBenzinga· Mar 3, 2026
• Longeveron Announces Closing Of Up To $17.5 Million Public Offering
  neutralBenzinga· Aug 11, 2025